RNA, U2 small nuclear 72, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-72P profile across patient tissues and cancer cell-line models. RNU2-72P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RNU2-72P is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, RNU2-72P RNA expression shows 5,782 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight CESC, KIRC, and COAD as cancer lineages where RNU2-72P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-72P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-72P survival associations across molecular data types. RNU2-72P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-72P RNA expression–survival associations across cancer types. High RNU2-72P expression shows unfavorable associations in CESC, DLBC, LGG, LUAD, READ and PRAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RNU2-72P RNA expression.
This table summarizes RNU2-72P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-72P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-72P shows higher tumor expression in KIRC. The KIRC box plot shows higher RNU2-72P RNA expression in tumor versus normal tissue (log2 FC = +0.097, t-test p = .010).
This table shows molecular features associated with RNU2-72P in patient tissues and cancer cell lines. In patient samples, RNU2-72P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
